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Cell–cell adhesion genes CTNNA2 and CTNNA3
are tumour suppressors frequently mutated in
laryngeal carcinomas
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Laryngeal squamous cell carcinoma is a frequent and signiﬁcant cause of morbidity and
mortality. Here we explore the biological basis of this aggressive tumour, and identify two
cell–cell adhesion genes as recurrently mutated in this malignancy. We ﬁrst perform exome
sequencing of four laryngeal carcinomas and their matched normal tissues. Among the 569
genes found to present somatic mutations, and based on their recurrence or functional
relevance in cancer, we select 40 for further validation in 86 additional laryngeal carcinomas.
We detect frequent mutations (14 of 90, 15%) in CTNNA2 and CTNNA3-encoding a-catenins.
Functional studies reveal an increase in the migration and invasive ability of head and neck
squamous cell carcinoma cells producing mutated forms of CTNNA2 and CTNNA3 or in cells
where both a-catenins are silenced. Analysis of the clinical relevance of these mutations
demonstrates that they are associated with poor prognosis. We conclude that CTNNA2 and
CTNNA3 are tumour suppressor genes frequently mutated in laryngeal carcinomas.
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H
ead and neck carcinomas are an anatomically diverse and
molecularly heterogeneous group of malignancies invol-
ving the oral cavity and oropharynx, nasopharynx,
hypopharynx, larynx, ear, nasal cavity and paranasal sinuses, as
well as the thyroid, parathyroid and salivary glands. Head and
neck squamous cell carcinoma (HNSCC) represents 490% of all
head and neck cancers and arises from the mucosa of the upper
aerodigestive tract. With a worldwide incidence exceeding half a
million cases annually, HNSCC poses a major health risk and is
one of the leading causes of mortality in developing nations1. The
most signiﬁcant risk factors to develop HNSCC remain tobacco
and alcohol abuse. It is now well established that HNSCC is a
heterogeneous disease, both at the molecular and clinical level,
which arises from a multistage pathogenesis process2. Despite
advances in the clinical classiﬁcation of the disease, a global
genomic perspective is still needed to shed light on the whole
mutational landscape and underlying molecular mechanisms
characteristic of this type of tumour. In this regard, recent works
of whole-exome sequencing of HNSCC have been published3,4. In
addition to identifying genes previously known to be involved in
HNSCC, such as TP53, CDKN2A, PTEN, PIK3CA and HRAS,
these studies have proposed NOTCH1 as a possible key tumour
suppressor gene in the HNSCC carcinogenic process. Other genes
such as IRF6, TP63 and FBXW7 have also been described in these
reports as important HNSCC-mutated genes. However, these
next-generation sequencing HNSCC studies did not identify
novel cancer-related genes.
Here we report the characterization of the mutational landscape
of four laryngeal squamous cell carcinomas, with a validation
set of 86 additional cases. To our knowledge, this is the ﬁrst high-
throughput genomic study on a large cohort of biologically
homogeneous laryngeal squamous cell carcinoma samples surgi-
cally isolated from patients who had not received chemotherapy or
radiotherapy before surgery. This approach circumvents the noise
derived from the biological and clinical heterogeneity that hindered
previous studies on HNSCC in which laryngeal carcinomas were
only minimally represented. This strategy has allowed us to unveil
frequent somatic mutations targeting cell–cell adhesion genes
CTNNA2 and CTNNA3 in larynx cancer. In this work, we also
provide functional analyses demonstrating that cells expressing
mutated versions of CTNNA2 and CTNNA3 exhibit enhanced
migration and invasion capabilities, a behaviour recapitulated by
HNSCC cells in which expression of these a-catenins was silenced.
Finally, we perform clinical analyses that show a poor prognosis in
patients with CTNNA2 or CTNNA3 mutations.
Results
CTNNA2 and CTNNA3 mutations in larynx cancer. To better
understand the molecular pathogenesis of HNSCC and to mini-
mize the known biological and molecular heterogeneity among
tumours originated from different head and neck anatomical
locations such as the oral cavity, pharynx, larynx and paranasal
sinuses5,6, we have carried out a mutational analysis of laryngeal
carcinomas. To this purpose, we ﬁrst performed whole-exome
sequencing of matched tumour and normal samples from four
individuals with laryngeal squamous cell carcinoma and a clinical
history of tobacco and alcohol abuse (Table 1). The tumour
biopsies were taken during the surgical procedure and none
of the patients had received chemotherapy or radiotherapy before
surgery. We achieved 106-fold mean sequence coverage of
targeted exonic regions. On average, 89% of the exome positions
were covered by more than eight reads with Phred quality higher
than 30 (callable exome; Supplementary Table S1). We identiﬁed
a median of 260 somatic mutations per case, which represents
about seven mutations per megabase of sequenced DNA
(Supplementary Data 1). This mutational rate agrees with data
recently reported for head and neck carcinomas from different
locations3,4 as well as for other smoking-related malignancies7.
The most common substitution found in these laryngeal carci-
nomas was G4T/C4A (Fig. 1), which is also consistent with
data from studies on other smoking-related tumours7. Analysis of
the identiﬁed somatic mutations predicted that 606 of them result
in protein-coding changes in 569 genes (Supplementary Data 2).
To determine whether any of these genes was recurrently muta-
ted, we next analysed a validation set of 86 laryngeal squamous
cell carcinomas from patients who had not received chemother-
apy or radiotherapy before surgery. To avoid any putative
mutational bias derived from heterogeneity among HNSCCs
from different sites5,6, we carefully selected patients whose
tumours were unequivocally diagnosed as laryngeal squamous
cell carcinomas (Supplementary Data 3). To perform the vali-
dation analysis, we focused on 40 genes mutated in more than
one of the four exome-sequenced tumours or whose biological
function was presumed to be relevant for cancer development
(Supplementary Data 4). Then, we used Somatic Mutation
Identiﬁcation in Pooled Samples (SMIPS), a pooled sequencing
Table 1 | Biological characteristics of HNSCC samples analysed by whole-exome sequencing.
Code Age Location pTNM Stage Surgery Status OS
L000 71 Supraglottic T4 N2c M0 G2 R0 4A TþBND Dead 6
L004 64 Supraglottic T4a N0 M0 G1 R0 4A TþBND Alive 26
L005 56 Supraglottic T4a N2c M0 G2 R0 4A Pþ BND Dead 26
L006 65 Glottic T4a N2b M0 G3 R0 4A TþBND Dead 18
BND, Bilateral neck dissection; OS, overall survival (months); pTNM, pathological tumour node metastasis stage; P, Partial laryngectomy; T, total laryngectomy.
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Figure 1 | Mutational proﬁle of whole-exome-sequenced samples from
patients with laryngeal carcinoma. Each mutation type is expressed as
reference base4mutated base in either strand. The number in each group
is the aggregate of all four exomes.
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strategy with the ability to identify recurrent mutations, as
assessed in previous genomic studies of chronic lymphocytic
leukaemia8–10. Analysis of this additional set of 86 laryngeal
carcinomas led us to identify CTNNA2 and CTNNA3, encoding
cell–cell adhesion a-catenins11,12, as novel recurrently mutated
genes in this aggressive malignancy (Fig. 2a). We found seven
tumours with mutations in CTNNA2 and six tumours with
mutations in CTNNA3, including one case harbouring two dif-
ferent missense mutations in this latter gene (Table 2). These cell–
cell adhesion genes were among the most frequently mutated
genes (15% when considered together) in our patient series.
Analysis of the mutational spectrum in both a-catenin genes is
consistent with the hypothesis that CTNNA2 and CTNNA3 might
act as tumour suppressor genes (Fig. 2a). Thus, 13 of the
identiﬁed mutations were predicted to be deleterious to the
encoded protein through 10 missense mutations of the vinculin-
like domains, with a further 3 truncating the protein through the
introduction of premature stop codons (Table 2). Further, no
obvious clustering of mutations was observed when the structure
of the vinculin domains was taken into account (Fig. 2b).
Exploration of the COSMIC database13 revealed that mutations
in both a-catenin genes have been annotated in different
malignancies (Fig. 2a), whereas some CTNNA3 mutations have
been recently found in non-small cell lung carcinomas14. Further,
a very recent analysis of the cbioportal database15 has revealed the
annotation of many CTNNA2 and CTNNA3 mutations in a
spectrum of different malignancies, whereas the Cancer Cell Line
Encyclopedia16 has annotated 83 and 19 different cancerous cell
lines with mutations in CTNNA2 and CTNNA3, respectively.
Collectively, these data reinforce that CTNNA2 and CTNNA3
mutations are present in numerous cancer types and expand the
oncological interest of these a-catenin genes beyond laryngeal
carcinomas.
CTNNA2 and CTNNA3 mutations increase cell invasion.
CTNNA2 and CTNNA3 are key proteins of the adherens
junctional complex in epithelial cells and have a crucial role in
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Figure 2 | CTNNA2 and CTNNA3 mutations identiﬁed in laryngeal carcinomas. (a) Schematic representation of the human CTNNA2 and CTNNA3
adhesion proteins with different somatic alterations found in larynx cancer samples (black) and COSMIC (grey). Green blocks identify the two vinculin-like
domains in each a-catenin. CTNNA2 and CTNNA3 are depicted bound to cadherin (violet rectangles) through b-catenin (red arcs), and to actin
ﬁlaments (grey circles). (b) Structural localization of CTNNA2 and CTNNA3 mutations. The residues corresponding to mutations in CTNNA2 (red)
and CTNNA3 (orange) are shown over the structure of a CTNNA1 dimer (pdb id. 4IGG).
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cellular adherence11,12,17,18. To investigate the functional
relevance of CTNNA2 and CTNNA3 in HNSCC cells, we
performed both RNA interference and complementary DNA
overexpression studies of both genes and interrogated key
biological processes for tumour progression. We ﬁrst carried
out a cell adhesion proﬁle assay, which revealed that silencing and
overexpression of CTNNA2 and CTNNA3 mainly affected
laminin-dependent adhesion of HNSCC cells SCC-2 (Fig. 3a)
and SCC-40 (Fig. 4a and Supplementary Fig. S1). Subsequently,
we analysed by time-lapse microscopy the capacity of these cells
to migrate through a scratch wound in laminin-coated plates.
These experiments revealed that CTNNA2 and CTNNA3 silencing
confers SCC-2 cells (Fig. 3b, Supplementary Movies 1 and 2) and
SCC-40 cells (Fig. 4b) an enhanced ability to migrate through the
wound compared with control cells.
We next evaluated the invasive capacity of HNSCC cells under
conditions of loss- or gain-of-function of these a-catenins. We
found that CTNNA2- and CTNNA3-silenced clones showed
enhanced ability to invade a Matrigel matrix, whereas cells
overexpressing these a-catenin genes exhibited a considerably
reduced invasive ability (Figs 4c and 5). To gain further insight
into the role of the mutations identiﬁed in CTNNA2 and
CTNNA3, we performed site-directed mutagenesis experiments
on some selected residues of both a-catenin genes. SCC-2 cells
overexpressing CTNNA2-S132Y, CTNNA2-E266*, CTNNA3-
C622F or CTNNA3-R628P showed signiﬁcantly enhanced ability
to invade a Matrigel matrix when compared with cells over-
expressing wild-type CTNNA2 or CTNNA3 cDNA, and had
similar phenotype to the parental controls (Fig. 5). Collectively,
these results are consistent with the hypothesis that CTNNA2
and CTNNA3 are tumour suppressor genes, whose genetic
inactivation endows HNSCC cells with migration and invasion
advantages, which may contribute to the progression of larynx
cancer.
CTNNA2 and CTNNA3 silencing alters b-catenin signalling. To
further explore the molecular mechanisms underlying the
observed alterations caused by CTNNA2 and CTNNA3 muta-
tions, we next investigated how changes in these genes affect
relevant biochemical pathways involving cell–cell adhesion. As
these a-catenins interact with b-catenin11,12, we examined the
phosphorylation status of this downstream component of the
Wnt pathway, which is altered in many types of cancer19,20. We
found that overexpression of CTNNA2 and CTNNA3 in HNSCC
SCC-2 cells grown on laminin caused a substantial decrease in
phosphorylation levels of b-catenin at Ser552 (Supplementary
Fig. S2). Conversely, silencing of CTNNA2 and CTNNA3 and
overexpression of CTNNA2-S132A, CTNNA2-E266* and
CTNNA3-R628P in HNSCC cells increased phosphorylation
levels of this b-catenin residue (Supplementary Fig. S2). Phos-
phorylation levels of b-catenin at other Ser and Thr residues did
not signiﬁcantly change after overexpression or silencing of
CTNNA2 and CTNNA3 (Supplementary Fig. S2). Phosphoryla-
tion of b-catenin at Ser552 results in its translocation from cell–
cell contacts into the nucleus21, and once b-catenin is
translocated, it activates transcription factors of the TCF/LEF-1
family22. Therefore, we performed TCF/LEF-1 luciferase reporter
assays to evaluate the putative changes in the activity of
these transcription factors caused by CTNNA2 and CTNNA3
mutations in laryngeal carcinomas. Silencing of CTNNA2 and
CTNNA3 in SCC-2 and SCC-40 cells led to a signiﬁcant increase
of TCF/LEF-1 transcriptional activity when compared with
control cells (Figs 4d and 6). In contrast, upregulation of
CTNNA2 and CTNNA3 in HNSCC SCC-2 cells was associated
with reduced luciferase activity (Fig. 6). Similarly, overexpression
of S132A and E266* CTNNA2 mutants as well as that of C622F
and R628P CTNNA3 mutants in these cells increased the TCF/
LEF-1 transcriptional activity compared with cells overexpressing
wild-type genes (Fig. 6). Thus, downregulation of CTNNA2 and
CTNNA3 increases phosphorylation of b-catenin at Ser552, which
might cause its dissociation from cell–cell contacts, removing the
tightly regulated transcriptional control of genes that inhibit
cellular motility and invasion, and ﬁnally favouring tumour
progression.
CTNNA2 and CTNNA3 mutations are associated with poor
prognosis. To evaluate the impact of CTNNA2 and CTNNA3
mutations in the clinical outcome of larynx cancer patients, we
examined the available clinical data of 86 patients from the vali-
dation series, including 7 with mutations in CTNNA2 and/or
CTNNA3 (Supplementary Data 3). Then, we constructed a mul-
tivariate Cox proportional hazards model including the tumour
node metastasis classiﬁcation of each tumour as a co-variable. This
analysis showed that patients in a given stage are four times more
likely to die if they have tumours with CTNNA2 or CTNNA3
mutations (hazard ratio: 4.209; 95% conﬁdence interval, 1.045–
16.949; P¼ 0.027, log-rank test), which suggests that mutations in
these genes are associated with worse clinical prognosis.
Discussion
HNSCC is an aggressive cancer that arises from the epithelial
mucosa of the upper aerodigestive track. In recent years, many
research projects have tried to gain a comprehensive view of this
disease, including two recent works describing for the ﬁrst time
the heterogeneous genomic landscape of HNSCC3,4. However,
survival of these patients has not improved during the last decade,
nor has any novel candidate gene related to the progression of this
disease been identiﬁed in the intervening years. We decided to
investigate two factors that may contribute to these disappointing
results, namely, the low level of mutational recurrence affecting
some genes that drive cancer progression and the anatomical and
molecular heterogeneity of HNSCC. Accordingly, this work has
focused on the identiﬁcation and functional analysis of new genes
recurrently mutated in a homogeneous cohort of patients suffering
from laryngeal squamous cell carcinoma.
To identify novel candidate drivers of laryngeal cancer
progression, we ﬁrst analysed the genomes of four tumours
compared with the constitutive genome of each patient.
A literature-guided examination of the results of this analysis
Table 2 | Somatic mutations affecting CTNNA2 and CTNNA3
in the validation series.
Gene Case Location Mutation Condel
score
Condel
prediction
CTNNA2 HN05 Glottic E76* — Truncating
CTNNA2 HN35 Supraglottic S132Y 0.942 Deleterious
CTNNA2 HN22 Supraglottic E266* — Truncating
CTNNA2 HN03 Supraglottic L434* — Truncating
CTNNA2 HN24 Glottic S597G 0.792 Deleterious
CTNNA2 L000 Supraglottic M725I 0.645 Deleterious
CTNNA2 L004 Supraglottic A761S 0.367 Neutral
CTNNA3 HN03 Supraglottic E413V 0.652 Deleterious
CTNNA3 HN67 Supraglottic A468P 0.76 Deleterious
CTNNA3 HN51 Supraglottic V492F 0.591 Deleterious
CTNNA3 HN56 Supraglottic V607L 0.585 Deleterious
CTNNA3 HN22 Supraglottic C622F 0.689 Deleterious
CTNNA3 L000 Supraglottic R628P 0.645 Deleterious
CTNNA3 HN56 Supraglottic D696N 0.622 Deleterious
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led us to select 40 genes as potentially interesting novel candidates
whose mutation might drive the progression of this tumour. We
then used SMIPS, a pooled sequencing strategy, to determine
which of these genes were indeed recurrently mutated in an
extended cohort of 86 patients. This allowed us to identify the a-
catenins CTNNA2 and CTNNA3 as new putative drivers of
laryngeal carcinoma. Thus, these a-catenins were found altered in
B15% of all the larynx cancer cases, with a uniform distribution
amongst glottic and supraglottic tumours. In excellent support of
our ﬁndings, data mining of the whole-exome data from Stransky
et al.4 revealed the occurrence of CTNNA2 mutations in three
HNSCC patients. In this report, two of the three tumours
originated from the larynx, whereas the remaining tumour
was from the closely related and anatomically contiguous hypo-
pharynx, providing further support to the results presented
herein. Mutations in CTNNA3 were not identiﬁed in the study by
Stransky et al.4, although this is probably because of the low
number of larynx tumours examined (n¼ 15). This result
suggests that tumours from the diverse anatomical locations
constituting HNSCC may each be driven through mutation of
distinct sets of genes and have important implications for patient
stratiﬁcation to try to improve prognostic and therapeutic
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Figure 3 | Adhesion proﬁle and migration of SCC-2 cells after silencing or overexpression of CTNNA2 and CTNNA3. (a) Following CTNNA2 and
CTNNA3 silencing, binding capacity of SCC-2 on different extracellular matrix components was assessed. Afﬁnity is expressed as relative ﬂuorescence
units (RFU). ‘i’ refers to CTNNA2 or CTNNA3 silenced cells, and ‘o’ to cells overexpressing CTNNA2 or CTNNA3. Col I, type-I collagen; Col II, type-II
collagen; FN, ﬁbronectin; LN, laminin. Statistical analyses were performed by Student’s t-test with *Po0.05 and **Po0.01. Error bars represent
mean±s.e.m. of three biological replicates. (b) Distance covered by the migration edge from the initial site was measured at different times and graphically
represented. Pictures at different times from a representative assay are shown. Statistical analyses were performed by Student’s t-test with *Po0.05 and
**Po0.01. Error bars represent mean±s.e.m. of three to ﬁve biological replicates. Scale bars, 250 mm.
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approaches. In support of this, recently identiﬁed mutations of
the TERT promoter in HSNCC displayed clear anatomical
selectivity in oral cavity tumours, with 11 of 12 cancers with
TERT promoter mutations originating from the oral tongue,
despite the fact that only 23 of the total 70 HSNCC tumours were
of oral tongue origin23.
In further support of our ﬁndings, analysis of the COSMIC,
cbioportal and Cancer Cell Line Encyclopedia databases13,15,16
has revealed the annotation of many CTNNA2 and CTNNA3
mutations in a spectrum of different malignancies and tumour
cell lines. These genomic data reinforce that a-catenin mutations
are driver events in numerous cancer types and emphasize the
need for their functional validation. The lack of any obvious
primary or structural clustering in the mutations affecting
CTNNA2 and CTNNA3, and the fact that a number of them
are predicted to cause premature stop codons in the encoded
proteins, suggests that these mutations might prompt a loss of
function in these catenins. To delve into this hypothesis, we ﬁrst
tested whether silencing or overexpression of these genes prompts
HNSCC cells to display any cancer-related phenotype. These
experiments revealed an increase in the migration and invasion
capacities of cells from which these catenins had been ablated.
Although the E-cadherin-a-catenin system is assumed to regulate
cell–cell contacts, our result is consistent with recent reports that
link E-cadherin with integrin-mediated cell–matrix adhesion in
the context of tumour progression24. Notably, we also observed
the opposite phenotype (for example, a decrease in migration and
invasion capacities) in cells overexpressing any of these genes.
This observation allowed us to directly test the functional con-
sequences of the described mutations. Thus, further experiments
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Figure 4 | Cellular features and b-catenin transcriptional activity of SCC-40 cells after silencing of CTNNA2 and CTNNA3. (a) Following CTNNA2
and CTNNA3 silencing (top), binding capacity of SCC-40 on different extracellular matrix components was assessed (bottom). Col I, type-I collagen;
Col II, type-II collagen; FN, ﬁbronectin; LN, laminin. Afﬁnity is expressed as relative ﬂuorescence units (RFU). (b) Distance covered by the migration edge
from the initial site was measured at different times and graphically represented. Migration pictures at different times from a representative experiment
are shown. (c) CTNNA2 and CTNNA3 silencing increased invasive capacity of SCC-40 cells. Number of invasive cells were counted and graphically
represented. (d) b-catenin transcriptional activity in SCC-40 cells following CTNNA2 and CTNNA3 interference. TOP, reporter with optimal Tcf-binding site;
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showed that overexpression of recombinant CTNNA2 and
CTNNA3 proteins harbouring several of the laryngeal carci-
noma mutations cannot replicate the functional consequences
of the overexpression of their wild-type counterparts. Further,
the overexpression of some of these mutants seems to mimic
the corresponding ablation-associated phenotype, despite the
presence of the wild-type protein in those cells. This observation
is consistent with a putative dominant-negative effect for these
mutations. Taken together, these experiments suggest that
CTNNA2 and CTNNA3 are tumour suppressor genes, and
mutations in these genes in larynx cancer patients cause loss of
function in both a-catenin proteins, which leads to increased
migration and invasion capabilities.
We then asked whether the functional changes found in these
experiments could be attributed to the known role of both a-
catenins as cell–cell adhesion proteins linking b-catenin to the
cytoskeleton. Failure to fulﬁl this role might lead to deregulated
release of b-catenin to the nucleus, the consequences of which are
consistent with the observed phenotype. We ﬁrst examined the
phosphorylation status of b-catenin, which is altered in
many types of cancer16,17. Interestingly, we found increased phos-
phorylation levels at a Ser residue implicated in the translocation
of b-catenin from cell–cell contacts into the nucleus, in
CTNNA2- and CTNNA3-silenced SCC-2 cells21. Nuclear
translocation of b-catenin activates the transcription of TCF/
LEF-1 family factors22, and, accordingly, TCF/LEF-1 luciferase
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reporter assays revealed a signiﬁcant increase of TCF/LEF-1
transcriptional activity when CTNNA2 and CTNNA3 were
ablated. Similar to the previous functional assays, over-
expression of wild-type CTNNA2 and CTNNA3 also led to a
measurable phenotype, with decreased b-catenin phosphorylation
and TCF/LEF-1 transcriptional activity. As expected, over-
expression of CTNNA2 and CTNNA3 mutants failed to
replicate this wild-type phenotype, reinforcing the proposal that
the described mutations impair the biological role of both
a-catenins. These results suggest that acquisition of mutations in
these a-catenins may inactivate a transcriptional network of genes
that inhibit tumour invasion and progression24–26. Finally, our
clinical data support an important role of CTNNA2 and CTNNA3
mutations on the natural history of patients with laryngeal
carcinoma and are associated with worse clinical prognosis.
In summary, this work has identiﬁed CTNNA2 and CTNNA3
as novel cell–cell adhesion genes frequently mutated in larynx
cancer. Functional and clinical studies strongly suggest that both
genes may act as tumour suppressors, which is consistent with
the growing idea that the vast majority of HNSCC tumours
harbour many inactivating mutations. Therefore, these a-catenins
and their associated pathways offer new candidate targets for
the development of strategies that may contribute to the future
treatment of laryngeal carcinomas.
Methods
DNA isolation from human specimens. We obtained surgically resected
tumour samples and matched blood samples from each patient with laryngeal
carcinoma (Table 1). All but one were men, all strong smokers and 62 (83%) heavy
drinkers. Median age was 63 years (44–90). None of the patients received
chemotherapy or radiotherapy before the surgical treatment. All the patients were
treated surgically and 24 (32%) received adjuvant radiotherapy. Forty-nine (65%)
were alive at last follow-up (median follow-up 40 months (0–192). The patholo-
gical stage distribution in our cohort is representative of what it is expected in this
tumour (9 stage I, 17 stage II, 18 stage III and 31 stage IV). None had distant
metastases at the moment of diagnosis. To obtain tumour genomic DNA,B10mg
of fresh frozen tumour tissue were lysed in 360 ml of ATL buffer supplemented with
40ml of proteinase K for 2–16 h. After complete macroscopic digestion, the lysate
was mixed with 400 ml of AL buffer to homogenization, and then 400 ml of 100%
ethanol were added, followed by thorough vortexing for 15 s and 5min incubation
at room temperature. Genomic DNA was then precipitated by 10min centri-
fugation at 4 C and 20,000 g, washed with 70% ethanol, air-dried and resuspended
in 50–100 ml of AE buffer. ATL, AL, proteinase K and AE buffer were from Qiagen.
Germline genomic DNA was obtained from blood samples using the Flexigene
kit (Qiagen), according to manufacturer’s instructions. The experiments were
conducted in accordance with the Hospital Universitario Central de Asturias Ethics
Committee, and written informed consent was obtained from each individual
providing biological samples.
Exome enrichment. Three micrograms of genomic DNA from each sample were
sheared and used for the construction of a paired-end sequencing library as
previously described in the paired-end sequencing sample preparation protocol
provided by Illumina27. Enrichment of exonic sequences was then performed for
each library using the Sure Select Human All Exon Kit 50Mb (Agilent
Technologies) following the manufacturer’s instructions. Exon-enriched DNA was
pulled down by magnetic beads coated with streptavidin (Invitrogen), and was
followed by washing, elution and 18 additional cycles of ampliﬁcation of the
captured library. Exon enrichment was validated by real-time PCR in a 7300
Real-Time PCR System (Applied Biosystems) using a set of two pairs of primers to
amplify exons and one pair to amplify an intron. Enriched libraries were sequenced
using two lanes of an Illumina GAIIx sequencer.
Read mapping and processing. For exome sequencing, reads from each library
were mapped to the human reference genome (GRCh37) using Burrows-Wheeler
Aligner28 with the sampe option, and a BAM ﬁle was generated using SAMtools29.
Reads from the same paired-end libraries were merged and optical or PCR
duplicates were removed using Picard (http://www.picard.sourceforge.net/
index.shtml). Statistics about the number of mapped reads and depth of coverage
for each sample are shown in Supplementary Table S1. For the identiﬁcation of
somatic substitutions, we used the Sidro´n algorithm, which has been previously
described8. The frequencies of machine error were estimated by examining 3 105
likely homozygous positions (coverage higher than 15, fraction of non-reference
bases lower than 0.1). Because of the contamination of tumour samples with
normal tissue, the cutoff S-values were lowered to 11 for positions with coverage
higher than 20. The validation rate of the somatic mutations detected by Sidro´n
was higher than 90% as assessed by the Sanger sequencing (Supplementary Data 5).
Somatic mutation identiﬁcation in pooled samples. To discover recurrent
somatic mutations in the validation series, we performed a screening in a set of 86
additional laryngeal carcinoma cases (Supplementary Data 3) using a combination
of pooled samples, PCR ampliﬁcation and high-throughput sequencing. We
used a modiﬁed method for the analysis of pooled samples30. Brieﬂy, we ampliﬁed
each selected exon from two pools containing equal amounts of tumour and
normal DNA, respectively, from the patients. The primers used in this step are
described in Supplementary Data 6. To obtain sufﬁcient coverage, we mixed equal
amounts of the resulting 466 amplicons in four pools for each sample. Each
pool was sequenced in one lane of an Illumina GAIIx sequencer for an average
coverage of about 105 over 225,698 bases.
Mutation validation. To deconvolute the sequencing data generated by SMIPS, we
analysed each tumour DNA from the validation set by using SNaPShot (Life
Technnologies) according to the manufacturer’s instructions. We performed two
separate SNaPShot reactions per tumour DNA, one for CTNNA2 and one for
CTNNA3, using the primers shown in Supplementary Table S2. The presence of the
corresponding mutation identiﬁed by SNaPShot was veriﬁed by the Sanger
sequencing using a 3130XL Genetic Analyser and the primers described in
Supplementary Data 6.
Cells and cell culture conditions. Human HNSCC cell lines SCC-2 and SCC-40,
kindly provided by Dr R. Grenman (Turku University, Finland), were cultured in
DMEM (Invitrogen) supplemented with 10% fetal bovine serum, 2% HEPES, 1%
non-essential amino acids and 1% penicillin-streptomycin-glutamine. Sanger
sequencing experiments showed that these cell lines have no deleterious mutations
in CTNNA2 or CTNNA3. For overexpression experiments, cells at 80% conﬂuence
were transfected using Lipofectamine 2000 (Invitrogen) with the full-length
human cDNA of CTNNA2 and/or CTNNA3 (Origene, RC208731 and RC226241,
respectively). For knockdown experiments, cells were transduced with a set of four
retroviral short-hairpin RNA vectors based on the pLKO.1 vector and designed to
speciﬁcally target human CTNNA2 and/or CTNNA3 transcripts (Origene, TG313667
and TG313666, respectively). HEK-293T cells were used for virus packaging.
CTNNA2 and CTNNA3 mutant DNAs were created using a Stratagene QuikChange
II Site-Directed Mutagenesis kit (Agilent Technologies). Transfected clones were
selected during 15 days with 400mgml 1 of G418 for overexpressing clones and
1.1mgml 1 puromycin for silencing clones. All cell lines were analysed by western
blot to conﬁrm overexpression or silencing of the selected genes.
Cell adhesion assays. The adhesion capacity of different cell pools was analysed
with the ECM Cell Adhesion Array kit (Colorimetric; EMD Biosciences,
ECM540 96 wells) following the manufacturer’s instructions. Brieﬂy, 6 105
HNSCC cells were incubated in the ECM Array during 3 h. After cell lysis, the
absorbance was measured at 485 nm using a Synergy H4 Hybrid reader. All data
are the mean of three independent experiments.
Time-lapse migration assays. For cell migration assays, Ibidi-uncoated m-Dishes
(Ibidi 81151) were coated with laminin (15mgml 1; Sigma L2020) for 2 h at 37 C.
HNSCC cells (6 105) were seeded 6 h before performing the experiment on
coated dishes with culture inserts (Ibidi 80209) until complete adhesion. Inserts
were removed deﬁning a cell-free gap of around 500 mm, and cells were overlayed
with 2ml of culture media. Cell migration was time-lapse recorded in a Zeiss
Axiovert 200 microscope during 10 h for SCC-2 cells and 16 h for SCC-40 cells,
with an XL-multi S1 incubator and using Axiovision software. Migration areas at
different time points were calculated using ImageJ.
In vitro invasion assays. The in vitro invasion potential of HNSCC cells was
evaluated using Matrigel-coated invasion chambers with an 8-mm pore size (BD
Biosciences). For each experiment, 2.5 105 cells per well were allowed to migrate
for 27 h for SCC-2 cells and 40 h for SCC-40 cells through the Matrigel-coated
membranes using 3% fetal bovine serum as a chemoattractant. Cells that reached
the lower surface of the membrane were stained. The total number of cells in the
lower chamber was determined by visible light microscopy ( 4 magniﬁcation).
Luciferase reporter gene assays. To measure the transcriptional activity of the
b-catenin/Wnt signalling pathway, HNSCC cells were transfected with the indi-
cated vectors and seeded in 24-well plates at 1 105 cells per well. After 24 h, 0.6 mg
of TCF/LEF-1 reporter (pTOP-FLASH) or control vector (pFOP-FLASH) were
transiently co-transfected with 0.06 mg of TLRK vector and 0.2 mg of each DNA
construct (short-hairpin RNAs, full-length wild-type and mutated cDNAs,
respectively, for both CTNNA2 and CTNNA3) following the standard Lipofecta-
mine 2000 protocol (Invitrogen). Cells were incubated for 24 h, and then 10 ml out
of the 100 ml cell extract were used for measuring luciferase activity using the Dual
Luciferase Reporter Assay System kit (Promega).
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Western blot. Samples were subjected to SDS-PAGE and transferred to poly-
vinylidene diﬂuoride (0.45 mm pore size) membranes (Millipore). Blots were
blocked with 5% non-fat dry milk in TBS-T buffer (20mM Tris-HCl pH 7.4,
150mM NaCl and 0.05% Tween-20) for 1 h at room temperature and incubated
overnight at 4 C with 5% BSA in TBS-T with either 0.2 mgml 1 anti-CTNNA2
(TA300943, Origene) or 0.2 mgml 1 anti-CTNNA3 (13974-1-AP, Proteintech
Europe) and 1:1000 anti a-actin (A5441, Sigma). To evaluate the phosphorylation
status of b-catenin, we used b-catenin Antibody Sampler Kit (2951S, Cell Signal-
ing). Finally, the blots were incubated for 1 h at room temperature in 2.5% non-fat
dry milk in TBS-T buffer with 10 ngml 1 of goat anti-mouse (115-035-062,
Jackson ImmunoResearch) and donkey anti-rabbit (NA934V, GE Healthcare).
Then, blots were washed with TBS-T and developed with Immobilon Western
chemiluminescent horseradish peroxide substrate (Millipore). Chemiluminescent
images were taken with a Fujiﬁlm LAS3000 mini apparatus.
Statistical analysis. The SPSS Statistics 17.0 (SPSS Inc) package was employed to
correlate clinical and biological variables by means of Fisher’s test or non-para-
metric test when necessary. Survival curves were analysed according to the Kaplan
and Meier method and compared using the log-rank test. All statistical tests were
two-sided and the level of statistical signiﬁcance was 0.05.
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